QQ客服 官方微博 反馈留言

	OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm)
	Robson M.E., Im S.-A., Senkus E., Xu B., Domchek S.M., Masuda N., Delaloge S., Li W., Tung N.M., Armstrong A., Wu W., Goessl C.D., Runswick S., Conte P.F.
刊名	Journal of Clinical Oncology
	2017
卷号	35
ISSN号	0732-183X
URL标识	查看原文
语种	英语
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/3539321
专题	吉林大学白求恩第一医院
推荐引用方式 GB/T 7714	Robson M.E., Im S.-A., Senkus E., Xu B., Domchek S.M., Masuda N., Delaloge S., Li W., Tung N.M., Armstrong A., Wu W., Goessl C.D., Runswick S., Conte P.F.. OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm)[J]. Journal of Clinical Oncology,2017,35.
APA	Robson M.E., Im S.-A., Senkus E., Xu B., Domchek S.M., Masuda N., Delaloge S., Li W., Tung N.M., Armstrong A., Wu W., Goessl C.D., Runswick S., Conte P.F..(2017).OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm).Journal of Clinical Oncology,35.
MLA	Robson M.E., Im S.-A., Senkus E., Xu B., Domchek S.M., Masuda N., Delaloge S., Li W., Tung N.M., Armstrong A., Wu W., Goessl C.D., Runswick S., Conte P.F.."OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm)".Journal of Clinical Oncology 35(2017).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。